Fig. 2

Cumulative NMA evidence networks for overall survival: reference case including RCTs with 100% HER2+ patients and HER2+ subgroups. AC anthracycline (doxorubicin, epirubicin) + cyclophosphamide, Dose dense AC → T, or AC, either weekly or biweekly, E epirubicin, H Herceptin® intravenous (IV), HSC Herceptin® subcutaneous (SC), L lapatinib, NMA network meta-analysis, No Tx no treatment, T taxane (docetaxel, paclitaxel), TCH docetaxel + carboplatin + Herceptin® IV, V vinorelbine, X capecitabine